Tempus AI
AI-powered precision medicine for cancer and complex diseases
2015
Chicago, USA
Clinical / Enterprise
tempus.com
Overview
Tempus uses AI to analyze clinical and molecular data at scale, helping oncologists make data-driven treatment decisions. Its platform sequences tumors, identifies mutations, and matches patients with targeted therapies and clinical trials.
Why It's Notable
Largest library of clinical + molecular data. IPO'd in 2024. Used by 50% of US oncologists.
How It Works
Tumor tissue or blood is sent to Tempus labs for genomic sequencing. AI analyzes mutations against the world's largest clinicogenomic database to recommend targeted therapies, immunotherapies, and relevant clinical trials.
Key Features
Team & Background
Founded by Eric Lefkofsky (Groupon co-founder) after his wife's cancer diagnosis.
Disclaimer: This information is for educational purposes only. Health.AI does not endorse, sell, or receive compensation from any listed product. Always consult your healthcare provider before using any health technology. Product claims are based on manufacturer data and published research at the time of listing.